Cagrilintide vs Tesamorelin
Cagrilintide and Tesamorelin are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.
How they actually differ
Comparing the two: Cagrilintide is lipidated 37-residue amylin analogue, cys2–cys7 disulfide, c-terminal prolinamide, while Tesamorelin is full-length 44-residue ghrh analogue with trans-3-hexenoic acid modification — different molecular classes with different handling consequences; their leading degradation routes differ (fibrillation for Cagrilintide, aggregation at air–liquid interfaces from agitation for Tesamorelin), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
Cagrilintide — origin
Cagrilintide is an engineered analogue of human amylin (IAPP), the 37-residue hormone co-secreted with insulin from pancreatic beta cells. Its design problem was unusually specific: native amylin is strongly amyloidogenic, readily collapsing from helix into the beta-sheet conformation that seeds fibrils, which is what made a long-acting amylin drug difficult for decades. Cagrilintide carries six substitutions relative to human amylin (14E, 17R, 25P, 28P, 29P, 37P) — roughly 84% sequence homology — plus N-terminal acylation with a C20 fatty diacid through a gamma-glutamate linker.
Tesamorelin — origin
Tesamorelin is the complete 44-amino-acid sequence of human growth hormone-releasing hormone with a trans-3-hexenoic acid group attached at the N-terminus. That modification exists for one reason: native GHRH is cleaved almost immediately by dipeptidyl peptidase-4 at the N-terminal end, and the hexenoyl group blocks that cleavage.
Cagrilintide research themes
Cagrilintide binds the calcitonin receptor and all three amylin receptors (AMY1, AMY2, AMY3), which is why the literature sometimes classes it as a dual amylin and calcitonin receptor agonist.
A worked example of engineering a fibril-prone hormone into a stable long-acting analogue — salt-bridge helix stabilisation plus beta-sheet-breaking prolines.
The C20 diacid extends the half-life from minutes, for the short-acting analogue pramlintide, to roughly a week.
The most-studied context: co-administration with semaglutide, investigated in the REDEFINE trial programme.
Tesamorelin research themes
Full-length GHRH activity with DPP-4 resistance conferred by the N-terminal modification.
The most distinctive endpoint in its research literature.
Studied for effects on endogenous GH secretion patterns rather than direct GH substitution.
Investigated alongside body-composition endpoints in metabolic research.
Cagrilintide handling
- Never shake. Swirl gently and allow the cake to dissolve in its own time.
- Do not freeze reconstituted solution.
- Add diluent down the vial wall rather than directly onto the cake.
- Treat visible particulate or a settling precipitate as a rejected vial — for an amylin analogue this is the observable end of the fibrillation pathway, not a cosmetic issue.
Tesamorelin handling
- Allow several minutes for dissolution; do not accelerate with agitation or heat.
- Swirl gently — long chains aggregate at interfaces.
- Do not freeze reconstituted solution.
Both third-party tested
Every Popular Peptides batch of Cagrilintide and Tesamorelin is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
Cagrilintide reference
Related comparisons
Cagrilintide and Tesamorelin are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.